FindTrial
Sign In

Effects of Xindilizumab combined with albumin bound paclitaxel on functional status, NK cells, and tumor mutation burden in esophageal cancer patients

Effects of Xindilizumab combined with albumin bound paclitaxel on functional status, tumor mutation burden in esophageal cancer patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500095132
Enrollment
Unknown
Registered
2025-01-02
Start date
2025-01-13
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer (EC)

Interventions

Joint group:None
Chemotherapy group:None

Sponsors

Beijing Pinggu Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic standards of Western medicine, with reference to the "Standards for Diagnosis and Treatment of Esophageal Cancer"; 2. TNM stage is stage III.-IV.

Exclusion criteria

Exclusion criteria: 1. Patients with primary malignant tumors other than esophageal cancer; 2. Allergy and intolerance to the study drug; 3. Patients with mental or neurological diseases, immune system diseases; 4. Patients with severe liver, kidney, lung and other organ lesions or failure.

Design outcomes

Primary

MeasureTime frame
Clinical efficacy evaluation criteria;Karnofsky Performance Status Scale;Quality of Life;—

Secondary

MeasureTime frame
CYFRA21-1;Carcinoembryonic Antigen, CEA;—

Countries

China

Contacts

Public ContactWang Jingbo

Beijing Pinggu Hospital

18810799788@126.com+86 10 89992231

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026